The News Review:

- … keynote speaker at Duke Clinical Research Institute Administr…
- ‘Dramatic results’ for cancer drug
- CT May Better Predict Those At Higher Risk For Heart Disease
- Daily Times – Leading News Resource of Pakistan
- ICN plc Announces Appointment of Professor Dermot Kelleher to the…
- StressEraser Is Subject of Three Presentations at AAPB Conference
- NSABP and CIRG initiate enrollment in Phase III breast cancer study

… keynote speaker at Duke Clinical Research Institute Administr…
Carolina Newswire – Carolina Newswire (press release) – May 28, 2008
To learn more about Lorraine Stephens or this presentation send an email to lorraine@lorrainespeaks. About Duke Clinical Research Institute (DCRI): The DCRI is the world’s largest academic clinical research organization. They combine the clinical expertise and academic leadership of a premier teaching hospital with the full-service operational capabilities of a major contract research organization. With more than 950 faculty and staff the DCRI is capable of conducting any clinical research project from the smallest pilot study to truly global megatrials medical device trials to outcomes and quality of life analyses. For more information about the DCRI visit.

‘Dramatic results’ for cancer drug
AZ Central.com – May 28, 2008
“It got into my lungs spine and hips and was beginning to affect my life” said Coffman a retired Phoenix city worker who was treated on and off since 1991. He endured lung surgery three rounds of radiation therapy and an unsuccessful experimental treatment before getting the one that worked. The novel GDC-0449 molecule continues to undergo Phase I testing by TGen Clinical Research Services at Scottsdale Healthcare. Thanks to Coffman and eight other patients who took the oral medication researchers now know that GDC-0449 shrinks tumors for patients with advanced basal-cell carcinoma. According to Coffman he was lucky the end guy in a chain of coincidences. After five years the drug company happened to be ready to test the drug. The company picked Scottsdale Healthcare as the first clinical site.

CT May Better Predict Those At Higher Risk For Heart Disease
Science Daily – Science Daily (press release) – May 28, 2008
Scott Grundy professor of internal medicine. Reynolds Cardiovascular Clinical Research Center at UT Southwestern the American Heart Association and the National Institutes of Health supported the study. Adapted from materials provided by.

Daily Times – Leading News Resource of Pakistan
Daily Times – May 28, 2008
Addressing the concluding session of the day-long seminar on Clinical Research Management in Pakistan here on Saturday night she said a task force has been constituted to form the policy and it would be notified in a few days. The objective is mainly to mitigate the plight of a large section of people deprived of even basic healthcare facilities. This task force would be required to start planning by May and move forward with an integrated approach to build on past successes and also providing health cover for an increasingly impoverished public health sector. “I am looking for better planning and a coherent health policy that would integrate all sectors and enhance capacities in all healthcare spheres” she said. The government instead of sporadic interventions would ensure integrated goals supported by higher resources better planning and a serious investment in research and development.

ICN plc Announces Appointment of Professor Dermot Kelleher to the…
Earthtimes – May 28, 2008
Alongside his notable academic appointments he has served as a visiting research scientist with Lilly Research laboratories and has been a founder of a number of biotechnology companies. “We are delighted to welcome Professor Dermot Kelleher to the Board of ICN” commented Chairman Dr John Climax. “With his extensive experience in clinical research and in particular his academic insight into novel medicines he will prove an invaluable addition to the Board. ” ICN plc is a global provider of outsourced development services to the pharmaceutical biotechnology and medical device industries. The Company specializes in the strategic development management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. ICN teams have successfully conducted over 1900 development projects and over 2300 consultancy engagements across all major therapeutic areas. ICN currently has approximately 6150 employees operating from 69 locations in 36 countries.

StressEraser Is Subject of Three Presentations at AAPB Conference
Earthtimes – May 28, 2008
“The effects of a brief respiratory sinus arrhythmia intervention on State Anxiety and Heart Rate” presented by Fred Muench PhD and Leslie Sherlin PhD. Muench is Director of Clinical Research and Development for theStressEraser. Sherlin represents the Department of Mind-Body Medicineat the Southwest College of Naturopathic Medicine and Health Sciences inTempe Arizona and the Department of Psychology at Northern ArizonaUniversity in Flagstaff Arizona. Wyckoff is with the East ValleyNeurofeedback and Peak Performance Center in Mesa Arizona.

NSABP and CIRG initiate enrollment in Phase III breast cancer study
Pharmaceutical Business Review – May 28, 2008
BETH was developed through the collaborative efforts of the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Cancer International Research Group (CIRG). The study will be led by the two groups and will recruit approximately 3500 patients. The primary outcome measure of BETH will be invasive disease-free survival.